BRIEF

on Pentixapharm Holding AG (ETR:PTP)

Pentixapharm Holding AG: Q3 Outlook and Developments

Pentixapharm Holding AG recently reported on its Q3 updates, setting the stage for key developments in 2027. The Q3 update supports a 'BUY' recommendation ahead of the PANDA trial's initiation. Regulatory steps have progressed with FDA approval and ethics clearance in October, ensuring readiness for patient enrolment by Q1 2027.

Commercial partnerships are anticipated by mid-2027, offering validation for PentixaFor's market potential. A partnership would enhance infrastructure support and potentially reduce funding dependency. Meanwhile, PENTHERA offers a promising therapeutic approach coupled with PentixaFor's imaging technology for AML and multiple myeloma treatment.

Pentixapharm operates with a lower cost base, reporting an EBITDA loss of €2.4m in Q3. With convertible bonds extended and reduced personnel expenses, funding appears secure until 2028. The core opportunity in oncology remains robust, with research reaffirming a target price of €7.20 per share.

R. E.

Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Pentixapharm Holding AG news